Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_4
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 42 (66.7%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma

NCT02561546
unknownphase_4

rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors

NCT00902083
unknownphase_4

rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

NCT00902122

Clinical Trials (3)

Showing 3 of 3 trials
NCT02561546Phase 2

p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma

Unknown
NCT00902083Phase 4

rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors

Unknown
NCT00902122Phase 4

rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3